^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Esophageal Adenocarcinoma |
| Drug: | Yutuo (zimberelimab) (PD1 inhibitor) + domvanalimab (AB154) (TIGIT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EDGE-Gastric Arm A1: Phase 2 study of domvanalimab, zimberelimab, and FOLFOX in first-line (1L) advanced gastroesophageal cancer.
Published date:
11/07/2023
Excerpt:
Patients with previously untreated G/GEJ/E adenocarcinoma received D 1600 mg intravenously (IV) every 4 weeks (Q4W) + Z 480 mg IV Q4W + FOLFOX...Intent-to-treat ORR was 59% (95% CI 42 to 74). Clinical outcomes by PD-L1 status are in the Table...Addition of DZ to FOLFOX showed encouraging ORR and early PFS, particularly in pts with PD-L1-high tumors. The regimen is well tolerated.
Secondary therapy:
FOLFOX
DOI:
10.1200/JCO.2023.41.36_suppl.433248
Trial ID:
